All In Biotech

Drug Trial Radar · NCT03625037

First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma

A Phase 1/2, Open-label Safety Trial of GEN3013 in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma

Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

666

Actual

Start

Jun 26, 2018

Primary completion

Jan 2029

Study completion Jan 2029

Sponsor

Lead sponsor
GenmabIndustry
Sponsor type
Industry
Collaborators
AbbVie
First posted
Aug 10, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this trial is to measure the following in participants with relapsed and/or refractory B-cell lymphoma who receive epcoritamab, an antibody also known as EPKINLY™ and GEN3013 (DuoBody®-CD3xCD20): * The dose schedule for epcoritamab * The side effects seen with epcoritamab * What the body does with epcoritamab once it is administered * What epcoritamab does to the body once it is administered * How well epcoritamab works against relapsed and/or refractory B-cell lymphoma The trial consists of 3 parts: * a dose-escalation part (Phase 1, first-in-human \[FIH\]) * an expansion part (Phase 2a) * a dose-optimization part (OPT) (Phase 2a) The trial time for each participant depends on which trial part the participant enters: * For the dose-escalation part, each participant will be in the trial for approximately 1 year, which is made up of 21 days of screening, 6 months of treatment (the total time of treatment may be different for each participant), and 6 months of follow-up (the total time of follow-up may be different for each participant). * For the expansion and dose-OPT parts, each participant will be in the trial for approximately 1.5 years, which is made up of 21 days of screening, 1 year of treatment (the total time of treatment may be different for each participant), and 6 months of follow-up (the total time of follow-up may be different for each participant). Participation in the study will require visits to the sites. During the first month, participants must visit every day or every few days, depending on which trial part the participant enters. After that, participants must visit weekly, every other week, once a month, and once every 2 months, as trial participation ends. All participants will receive active drug, and no participants will be given placebo.

Conditions

  • DLBCL
  • High-grade B-cell Lymphoma (HGBCL)
  • Primary Mediastinal Large B-cell Lymphoma (PMBCL)
  • FL
  • MCL
  • Small Lymphocytic Lymphoma (SLL)
  • Marginal Zone Lymphoma (MZL)
  • Indolent B-cell Non-Hodgkin Lymphoma (iNHL)
  • Aggressive B-cell Non-Hodgkin Lymphoma (aNHL)

Interventions

  • EpcoritamabBiological

    Administered as specified in the treatment arm.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose-Escalation: Dose Limiting Toxicity (DLT)Time frame: During the first cycle (28 days)
  2. Dose-Escalation: Number of Participants with Adverse Events (AEs)Time frame: From first dose until the end of the safety follow-up period (Up to 1 year)
  3. Expansion: Overall Response Rate (ORR)Time frame: Up to 1.5 years
  4. Dose-OPT DLBCL, FL and MCL: Percentage of Participants with =>Grade 2 Cytokine Release Syndrome (CRS) Events and All Grade CRS EventsTime frame: From first dose until 7 days after second full dose (Day 28 for DLBCL; Day 35 for FL; Day 28-35 for MCL)

Locations

85 sites in 15 countries. Site status is shown where the registry gives one.

  • Arizona Mayo Clinic

    Phoenix, Arizona

  • University of California at San Francisco

    San Francisco, California

  • Colorado Blood Cancer Institute

    Denver, Colorado

  • H. Lee Moffitt Cancer Center and Research Institute

    Tampa, Florida

  • University of Iowa Hospital and Clinics

    Iowa City, Iowa

  • Ochsner Medical Center

    New Orleans, Louisiana

  • University of Michigan

    Ann Arbor, Michigan

  • Barbara Ann Karmanos Cancer Institute

    Detroit, Michigan

  • University of Nebraska Medical Center

    Omaha, Nebraska

  • Hackensack Meridian Health

    Hackensack, New Jersey

  • The Cleveland Clinic Foundation

    Cleveland, Ohio

  • OHSU Knight Cancer Institute

    Portland, Oregon

  • Hillman Cancer Center

    Pittsburgh, Pennsylvania

  • Rhode Island Hospital

    Providence, Rhode Island

  • Medical University of South Carolina

    Charleston, South Carolina

  • UT Southwestern

    Dallas, Texas

  • MD Anderson Cancer Center

    Houston, Texas

  • Monash Health

    Clayton, Australia

  • Concord Hospital

    Concord, Australia

  • St. Vincent Hospital

    Fitzroy, Australia

  • Royal Brisbane and Women's Hospital

    Herston, Australia

  • Royal Hobart Hospital RHH

    Hobart, Australia

  • St. George Hospital

    Kogarah, Australia

  • Cabrini Hospital

    Malvern, Australia

  • Sir Charles Gairdner Hospital

    Nedlands, Australia

  • Gold Coast Hospital

    Southport, Australia

  • Westmead Hospital

    Sydney, Australia

  • Tom Baker Cancer Care

    Calgary, Canada

  • Toronto-Sunnybrook Regional Cancer Ctr

    Toronto, Canada

  • Rigshospitalet

    Copenhagen, Denmark

  • Odense University Hospital

    Odense, Denmark

  • Vejle Hospital

    Vejle, Denmark

  • Helsinki University Hospital

    Helsinki, Finland

  • Kuopio University Hospital

    Kuopio, Finland

  • Tampere University Hospital

    Tampere, Finland

  • Hopital Henri Mondor

    Créteil, France

  • CHU Montpellier

    Montpellier, France

  • Hospital Saint-Louis

    Paris, France

  • Hospices Civils de Lyon Centre Hospitalier Lyon Sud

    Pierre-Bénite, France

  • Centre Henri Becquerel

    Rouen, France

Showing 40 of 85 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.